TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00470886

Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
Study: NCT00540852

Intervention type: DEVICE
Group type: OTHER
Intervention: Diffuse Optical Spectroscopy Imaging
Description: Diffuse Optical Spectroscopy Imaging
Study: NCT04756908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
Study: NCT01262989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: tamsulosin 0,4 mg (Boehringer Ingelheim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: tamsulosin 0,4 mg (Boehringer Ingelheim)
Study: NCT03314922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
Study: NCT02290678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventure-based Programming
Study: NCT04380519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH-104 80 mg
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64 mg
Description: solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Study: NCT04349800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo
Study: NCT02127957

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
Study: NCT00505401

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: recombinant HIV-1 Tat protein

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: recombinant HIV-1 Tat protein
Study: NCT00441064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Study: NCT02364635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icosabutate
Description: Single dose at each dose levet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icosabutate
Description: Single dose at each dose levet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icosabutate
Description: Single dose at each dose levet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icosabutate
Description: Single dose at each dose levet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: icosabutate
Description: Single dose at each dose levet
Study: NCT00280384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2014 (Botulinum toxin type B)
Description: A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2014 (Botulinum toxin type B) Placebo
Description: A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
Study: NCT04306861

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
Study: NCT01519869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
Study: NCT03427580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MERIT
Description: Metacognitive Reflection and Insight Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MERIT
Description: Metacognitive Reflection and Insight Therapy
Study: NCT02739971

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low AGEs diet
Description: Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care dietary guidance for Type 2 diabetes
Description: Oral and written instructions for standard of care dietary guidance for type 2 diabetes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care dietary guidance for Type 2 diabetes
Description: Oral and written instructions for standard of care dietary guidance for type 2 diabetes
Study: NCT01731418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, \& Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-as-usual
Description: Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills
Study: NCT04202172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction
Description: The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction
Description: The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography
Study: NCT03710083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian™ Sensor (3)
Description: Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
Study: NCT03198325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop of ART
Description: Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values \>50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
Study: NCT01043913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guarana extract
Description: Guarana extract 50mg q12 hours for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guarana extract
Description: Guarana extract 50mg q12 hours for 21 days
Study: NCT02283762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
Study: NCT00879645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide
Description: Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
Study: NCT02283762

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham-titration
Study: NCT02861274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker
Study: NCT03565419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glasses
Description: Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
Study: NCT01438736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)
Description: Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68 mg subdermal implant
Description: Etonogestrel 68 mg subdermal implant for 6 months
Study: NCT03969121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
Study: NCT02049606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAYLA tablet
Description: 1 Tablet twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CENATONE tablet
Description: 2 Tablets once a day
Study: NCT04049149

Intervention type: OTHER
Group type: OTHER
Intervention: Biogenetic explanation and endocrinologist intensive managment
Description: * JADE report and JADE APP~* Biogenetic explanation~* First-year intensive management by endocrinologists~* Follow up by their usual care doctors for continue treatment regimen maintenance.~* Yearly DM nurses follow up for blood taking and questionnaires
Study: NCT03969121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
Study: NCT00573573

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
Study: NCT04049149

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care management
Description: * JADE report and JADE APP~* Attend their usual care clinic for ongoing treatment~* Yearly DM nurses follow up for blood taking and questionnaires
Study: NCT02230319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT04121663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total arthroscopic rotator cuff repair
Description: The equivalence of the two devices was compared by using control and experimental instruments during the operation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total arthroscopic rotator cuff repair
Description: The equivalence of the two devices was compared by using control and experimental instruments during the operation
Study: NCT01137604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study: NCT00886600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
Study: NCT01137604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study: NCT01409811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive lumpectomy or mastectomy
Study: NCT00634101

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens
Study: NCT02273804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally following to the same dose regimen according to theoretical weight
Study: NCT02476266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
Study: NCT02010450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Blanket (Sleep Sack)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Item
Study: NCT02305810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Description: everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
Study: NCT01988584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood (hUCB) cells
Description: Autologous umbilical cord blood banked with the Cord Blood Registry.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood (hUCB) cells
Description: Autologous umbilical cord blood banked with the Cord Blood Registry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Infusion (Placebo)
Description: A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Infusion (Placebo)
Description: A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow derived mononuclear cells (BMMNCs)
Description: Autologous stem cells from bone marrow harvest.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow derived mononuclear cells (BMMNCs)
Description: Autologous stem cells from bone marrow harvest.
Study: NCT00759564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-70,429 and PF-03709270
Description: Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
Study: NCT02829801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAT and cognitive stimulation and rehabilitation of social tie.
Description: There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive stimulation and rehabilitation of social tie.
Description: There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered.
Study: NCT00886600

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Description: open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ)
Description: open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ)
Description: open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ)
Description: open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks